The landscape of obesity treatment in the United States is changing rapidly. New medications such as Ozempic and Zepbound are reshaping how patients and healthcare providers approach long-term weight management. Recent research presented at a major bariatric surgery conference suggests that the growing popularity of GLP-1 medications may be contributing to a significant drop in weight-loss surgery procedures across the country.
According to new findings shared at the annual meeting of the American Society for Metabolic and Bariatric Surgery, bariatric surgeries in the United States declined by more than 20% between 2022 and 2024. This marks one of the most notable shifts in obesity treatment trends over the past decade.
GLP-1 receptor agonists have become increasingly popular due to their ability to help patients lose weight without surgery. Drugs like Ozempic and Zepbound were initially developed to treat type 2 diabetes, but they quickly gained attention for their significant weight-loss effects.
These medications work by mimicking hormones that regulate appetite and blood sugar levels. Many patients report reduced hunger, smaller portion sizes, and steady weight reduction over time. As awareness around these medications grows, more individuals are exploring pharmaceutical treatment before considering surgery.
The study found that fewer than 177,000 bariatric procedures were performed in 2024. In comparison, the number exceeded 230,000 procedures in 2022, representing a 23% decline in just two years.
Researchers analyzed national surgical data collected from accredited bariatric centers between 2020 and 2024. The findings indicate that the rise of GLP-1 medications may be changing patient preferences, even as obesity rates in the United States remain high.
The report also highlighted changing trends in the types of weight-loss surgeries being performed. While sleeve gastrectomy remains the most common bariatric procedure, its share declined over the study period.
Here are some of the key findings:
Healthcare experts believe these changes may reflect evolving patient needs and physician recommendations. Some patients who do not achieve desired results from medications may eventually consider surgery, while others who previously had bariatric procedures may seek revisions or additional treatment options.
Although GLP-1 medications are gaining momentum, experts emphasize that surgery remains one of the most effective long-term treatments for severe obesity. Bariatric surgery has been shown to improve or resolve several obesity-related conditions, including type 2 diabetes, high blood pressure, and sleep apnea.
Dr. Tyler Cohn, associate professor at Loyola University Medical Center, noted that the research did not directly prove medications caused the decline in surgeries. However, he expressed concern that many patients may not fully understand all available treatment options.
Healthcare professionals also worry that millions of Americans with obesity still are not receiving any form of treatment at all. Despite increased public awareness, barriers such as cost, insurance coverage, social stigma, and limited access to care continue to prevent many patients from seeking help.
Experts say conversations about obesity treatment are improving, partly because GLP-1 drugs have brought greater attention to obesity as a chronic medical condition rather than simply a lifestyle issue.
There is no single solution that works for everyone. The best obesity treatment depends on factors such as body mass index, medical history, lifestyle, and long-term health goals.
GLP-1 medications may be appealing for patients who prefer a non-surgical option. However, these drugs often require ongoing use to maintain weight loss. Some individuals regain weight after stopping medication, which has become a growing concern among healthcare providers.
Bariatric surgery, on the other hand, typically produces more substantial and durable weight loss for patients with severe obesity. However, surgery also comes with recovery time, lifestyle adjustments, and potential risks associated with any major procedure.
Many obesity specialists now believe that the future of treatment may involve a combination of medication, lifestyle support, and surgery when appropriate.
The increasing popularity of GLP-1 medications has sparked broader public discussions about obesity treatment. Social media, celebrity endorsements, and extensive media coverage have all contributed to growing awareness around drugs like Ozempic.
This increased visibility may encourage more patients to seek medical guidance for obesity management. Experts say this could ultimately lead to better long-term outcomes if patients receive comprehensive education about all available treatment options.
Still, healthcare professionals caution against viewing obesity medications as a quick fix. Successful weight management often requires ongoing medical supervision, nutritional support, physical activity, and behavioral changes.
As obesity rates continue to climb, the demand for effective treatment options remains high. Researchers expect GLP-1 medications to continue influencing the obesity care landscape in the coming years.
At the same time, bariatric surgery is likely to remain an important treatment option, particularly for individuals with severe obesity or obesity-related complications.
Medical experts believe the key challenge moving forward will be ensuring that patients receive personalized treatment plans based on their individual health needs rather than temporary trends or social media influence.
The recent decline in bariatric procedures highlights how quickly the healthcare industry is evolving. Whether through medication, surgery, or combined therapies, obesity treatment is entering a new era focused on expanded options and greater patient awareness.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Weight-loss medications and bariatric surgery may not be appropriate for everyone. Always consult a qualified healthcare professional before making decisions regarding obesity treatment or weight management strategies. Findings presented at medical meetings are considered preliminary until published in a peer-reviewed medical journal.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.